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ABSTRACT
Objective. Emerging evidence suggests an important role for mast cells in vein graft
failure. This study addressed the hypothesis that perivascular mast cells regulate in
situ vascular inflammatory and proliferative responses and subsequent vein graft
neointimal lesion formation, using an optimized local mast cell reconstitution
method.
Methods and Results. Neointimal hyperplasia was induced by insertion of a vein
graft into the right carotid artery in wild type and mast cell deficient KitW-sh/W-sh
mice. In some experiments, mast cells were reconstituted systemically (tail vein
injection of bone marrow-derived mast cells) or locally (directly into the right neck
area) prior to vein grafting. Vein graft neointimal lesion formation was significantly
(P < 0.05) reduced in KitW-sh/W-sh mice. Mast cell deficiency reduced the number of
proliferating cells, and inhibited L-selectin, CCL2, M-CSF andMIP-3α expression in
the vein grafts. Local but not systemic mast cell reconstitution restored a perivascular
mast cell population that subsequently promoted neointimal formation in mast cell
deficient mice.
Conclusion.Our data demonstrate that perivascular mast cells play a key role in pro-
moting neointima formation by inducing local acute inflammatory and proliferative
responses. These results suggest that ex vivo intraoperative targeting of mast cells may
have therapeutic potential for the prevention of pathological vein graft remodeling.
Subjects Cardiology, Immunology, Pharmacology
Keywords Vein graft, Mast cells, Neointima
INTRODUCTION
Emerging evidence suggests that mast cells (MCs) play an active role in cardiovascular
diseases (Kennedy et al., 2013; Kritikou et al., 2015) such as arteriosclerosis (Ihara et al.,
1999; Kovanen, 2007; Sun et al., 2007a; Theoharides et al., 2001; Bot & Biessen, 2011; Bot,
Shi & Kovanen, 2015; Wezel et al., 2015), aortic aneurysm (Sun et al., 2007b; Swedenborg,
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Ma¨yra¨npa¨a¨ & Kovanen, 2011; Zhang et al., 2012; Sillesen et al., 2015) and neointimal
hyperplasia (Shiota et al., 1999; Fang et al., 2005; Jin et al., 2005; Jin et al., 2007). The
presence of MCs in vein grafts has been known for decades; but only recently has the net
contribution of these cells to vein graft disease been investigated. Earlier studies suggested
an association between vein graft vasospasm and MC-derived histamine (Cross et al.,
1988; Vural et al., 1999), while pharmacological inhibition of mast cell-derived chymase
reduced neointimal hyperplasia in vein grafts (Jin et al., 2007). Recent evidence using
mast cell-deficient KitW-sh/W-sh mice demonstrated a positive correlation between the
presence of MCs and vein graft neointima thickening (De Vries et al., 2013). In that
study, pharmacological inhibition of MCs also reduced vein graft hyperplasia with the
complement factor C5a proposed to be an endogenous MC activator in vein graft disease
(De Vries et al., 2013).
MCs can be reconstituted in c-Kit mutant mice by tail vein injection of wild type
(WT) bone marrow-derived mast cells (BMMCs) (Grimbaldeston et al., 2005). In the
present study, we demonstrate that correction of c-kit-mutation-induced MC deficiency
in KitW-sh/W-sh mice by local but not systemic MC reconstitution restored neointimal
formation to that seen in normal mice. Our results highlight the pivotal role played
by perivascular MCs in promoting neointimal formation by inducing local early acute
inflammatory and proliferative responses, and suggest vein graft ex vivo MC targeting as a
potential therapeutic strategy to improve long-term vein graft patency.
MATERIALS AND METHODS
Animals
Male wild type (WT) C57BL/6, either bred in-house (Biological Procedures Unit, Uni-
versity of Strathclyde) or purchased from Charles River (Margate, UK), and KitW-sh/W-sh
mice (originally sourced from Jackson Laboratories, USA and subsequently bred in-house)
were used in this study. All procedures on animals were performed in accordance with the
United Kingdom Home Office Guide on the Use of Animals (Scientific Procedures) Act
1986 (Project Licence 60/4114). All mice were allowed free access to normal chow diet and
water andmaintained on a 12-hour light and dark cycle.
Surgery
The mouse vein graft model used in this study was first established 17 years ago by Xu’s
group (Zou et al., 1998) and well characterized for studying neointima hyperplasia over the
past decade (Xu, 2004; Wu, Wadsworth & Kennedy, 2011). Briefly, mice were anesthetized
with sodium pentobarbital (60 mg/kg, i.p.) with appropriate analgesic cover (buprenor-
phine; 0.05 mg/kg body weight, s.c.). Depth of anesthesia was assessed by loss of the pedal
withdrawal reflex. The thoracic inferior vena cava was harvested from an isogenic donor
mouse. The right common carotid artery of the recipient mouse was isolated and cut in
the middle. A cuff made from a nylon tube was sleeved onto the distal arterial end. The
artery was everted back over the cuff and ligated onto the cuff with 8/0 silk suture (Ethicon,
Livingston, UK). The proximal arterial end was prepared in the same way. The vena cava
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segment was then sleeved onto the arterial ends in turn and fixed onto the cuff with 8/0
suture. At the study end point, mice were sacrificed by a rising concentration of CO2 unless
otherwise specified and vein grafts harvested at 1–3, 7, 14 and 28 days after surgery.
Bone marrow-derived mast cell (BMMC) reconstitution
Bone marrow cells were isolated from C57BL/6 mice and cultured in the presence of
murine IL-3 and stem cell factor (PeproTech, New Jersey, USA) for 4 weeks as previously
described (Sun et al., 2007a; Sun et al., 2007b). The phenotype of the BMMCs was
confirmed by flow cytometry with anti-c-Kit and anti-FcεRI antibodies (eBioscience,
Hatfield, UK). Systemic reconstitution of BMMCs is well established for restoration
of a mast cell population in mast cell-deficient mice (Grimbaldeston et al., 2005). The
recipient KitW-sh/W-sh mouse received 10million wild type BMMCs via tail vein injection.
Typically, BMMCs require around 9 weeks to migrate to peripheral tissues and re-establish
a detectable MC population. However, in our study, although systemic reconstitution
re-established mast cells in some organs, none were detected in perivascular locations.
Consequently, we established a new method of local reconstitution by injecting BMMCs
directly into the carotid artery region. Briefly, the recipient mouse was anesthetized and
the common right carotid artery was carefully exposed. BMMCs were injected around the
artery. The wound was closed with a 6/0 suture. Local reconstitution required only one
million BMMCs to establish a perivascular mast cell population in a similar range to WT
and this occurred within 4 weeks.
For all reconstitution experiments, interpositional vena cava to carotid artery vein
grafting was performed as outlined above and grafts were removed 4 weeks after to
measure neointima formation.
Histology and immunostaining
Vein grafts were perfusion fixed and kept in 10% formalin overnight before embedding in
paraffin. Serial sections (5 µm) were cut for each vein graft, and slides were evenly divided
into 5 groups from the proximal to the distal end of each vein graft. For each staining
experiment, a set of 5 slides (one slide from each group) from each vein graft was used.
The mean value of the 5 serial slides was used to present the value of the whole vein graft.
Haematoxylin and eosin (HE) staining was used for general morphology and planimetry
studies (Image pro plus;Media Cybernetics, Marlow, UK).
Mast cells within grafts were identified and quantified by Toluidine Blue (Sigma-
Aldrich, Dorset, UK) counterstained with fast red. MC identity was confirmed by Avidin
Texas red conjugate staining (Invitrogen—Life Technologies, Paisley, UK). Avidin Texas
red conjugate was added to de-waxed slides at a dilution of 1:250 in PBS and incubated
overnight. Detection was by means of a fluorescence microscope (Biorad Radiance 2100
on a Nikon TE300) with 488 nm line of Argon ion laser excitation, emission 515 nm, and
543 nm line of GreenHe/Ne laser excitation, emission 590 nm.
For immunostaining, slides were de-waxed and pressure-cooked for antigen retrieval.
As we previously demonstrated, cell proliferation peaks in the first week in mouse vein
grafts (Wu, Wadsworth & Kennedy, 2011); therefore, proliferating cell nuclear antigen
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(PCNA) analysis was used to quantify neointimal proliferation of vein grafts 7 days
after surgery (Grassia et al., 2009; Grassia et al., 2010) using a monoclonal mouse
anti-PCNA antibody (1:200, PC10; Sigma-Aldrich, Dorset, UK) and biotin-SP-AffiniPure
F(ab′)2 fragment goat anti-mouse IgG (H+L) secondary antibody (1:1000; Jackson
ImmunoResearch Laboratories, West Grove, Pennsylvania, USA). Slides were treated with
streptavidin–horseradish peroxidase (Dako, Ely, UK) and exposed to diaminobenzidine
chromogen (Dako) with haematoxylin counterstain, as routinely performed in our lab
(Grassia et al., 2009; Grassia et al., 2010). Nine sections from each vein graft were reviewed
and scored under blind conditions. Data are presented as the percentage of cells positive for
PCNA in the neointima 7 days after surgery.
Assessment of pro-inflammatory markers in vein graft protein
extract
The presence of pro-inflammatory markers in vein graft protein extracts at day 7 was
assessed by using RayBioMouse Atherosclerosis Antibody Array C (RayBiotech, Norcross,
Georgia, USA) according to the manufacturer’s instructions. The array consisted of 22
different soluble signaling factor antibodies spotted in duplicate onto a PVDFmembrane:
fibroblast growth factor-basic (bFGF), CD40 (TNFRSF5), eotaxin-1 (CCL11), G-CSF,
granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-γ , interleukin
(IL)-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-13, L-selectin (CD62L), monocyte chemoat-
tractant protein-1 (MCP-1)(CCL2), macrophage colony-stimulating factor (M-CSF),
macrophage inflammatory protein-3α (MIP-3α) (CCL20), P-selectin, RANTES (CCL5),
tumor necrosis factor-α (TNF-α), and vascular endothelium growth factor-A (VEGF-A).
Briefly, liquid nitrogen frozen vein grafts were crushed into powder and resuspended in
150 µL of high-salt extraction buffer (20 mMHepes pH 7.9, 10 mMNaCl, 0.2 mM EDTA,
25% v/v glycerol, 0.5 mM phenylmethylsulfonyl fluoride, 1.5 µg/mL soybean trypsin
inhibitor, 7 µg/mL pepstatin A, 5 µg/mL leupeptin, 0.1 mmol/L benzamidine, 0.5 mmol/L
dithiothreitol) and incubated at 4 ◦C for 30min with constant agitation. The samples were
then centrifuged for 15min at 6,000 g, and the supernatant aliquoted and stored at−80 ◦C.
Protein concentration was determined using the Bio-Rad protein assay Kit. Total extracts
were used to evaluate protein level by membrane-based antibody array. The membranes
were blocked with 10% bovine serum albumin in PBS and subsequently incubated with
lysates overnight at 4 ◦C. The membranes were washed with buffer supplied by the manu-
facturer, exposed to 500-fold diluted biotin-conjugated anti-cytokine antibodies at room
temperature for 2 h, washed and incubated with a 1,000-fold diluted HRP-conjugated
streptavidin for 1 h then immersed for 1 min in peroxidase substrate solution. The
signal intensity of each spot was quantified by ImageJ (http://imagej.nih.gov/ij/). The
signal intensity of the negative control was subtracted from each spot and the values were
normalized to the positive controls. The resulted were expressed as Arbitrary Units.
Serum cytokine detection assay
Concentration of bFGF, GM-CSF, IFN-γ , IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10,
IL-12, IL-13, IL-17, IFN γ -induced protein 10 (IP-10), KC (chemokine (C-X-C motif)
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ligand (CXCL) 1), MCP-1 (CCL2), monokine induced by IFN-γ (MIG), macrophage
inflammatory protein-1α (MIP-1α), TNF-α, and VEGF were assessed in serum at
day 7 using a 20-plex mouse cytokine assay (Macritchie et al., 2012; Sage et al., 2014)
(Invitrogen—Life Technologies, Carlsbad, California, USA) and analyzed using a Bio-Rad
Luminex 100 Plate Reader (Bio-Rad, Hemel Hempstead, United Kingdom).
Characterization of leukocyte population by flow cytometry
Flow cytometry of vein graft tissue was performed as previously described with minor
modifications (Macritchie et al., 2012; Hu et al., 2015). Briefly, 28 days after surgery WT
and KitW-sh/W-sh mice were placed under terminal anesthesia and perfused with 2 mM
EDTA (Sigma-Aldrich) in PBS via cardiac puncture to remove blood contamination from
vascular tissue. Following removal of vein grafts, a single cell suspension was obtained
by incubation of vein graft segments in an enzymatic suspension containing 450 U/ml
collagenase type I, 125 U/ml collagenase type XI, 60 U/ml hyaluronidase, 60 U/ml DNase
(all from Sigma-Aldrich) in PBS containing 20 mM Hepes at 37 ◦C for 1 h. Digested
vein grafts were then mechanically disrupted through a 40 µM cell strainer to release a
single cell suspension. Aliquots of cells were washed and resuspended in Fc block (2.4G2
hybridoma supernatant) for 25 min at 4 ◦C to block Fc receptors. Subsequently, cells
were incubated with Abs (in PBS containing 2% FCS) for 30 min at 4 ◦C. Following
washing, cells were analyzed on a MACSQuant Analyzer (Miltenyi Biotec, Bisley, UK)
and data analysis performed using FlowJo (Tree Star Inc., Olten, Switzerland). Abs used
were CD11b-PE-Cy7 (M1/70), CD11c-PE (N418) from eBioscience (Hatfield, UK),
CD45-APC-Cy7 (30-F11), CD3-PerCP (145-2C11) from BD Biosciences (Oxford, UK),
and B220-Brilliant Violet 421 (RA3-6B2) from Biolegend (Cambridge, UK). All the
antibodies used for flow cytometry analysis of the mouse vein graft had been validated on
cell suspensions from spleen/LNs untreated or treated with the enzyme digestion cocktail.
Statistics
One-way ANOVA was performed for multi-group comparison, followed by Tukey’s test.
Student’s t-test was applied for 2-group comparisons. In all cases, P < 0.05 was taken as
statistical significance.
RESULTS
Local rather than systemic MCs regulate vein graft neointimal
hyperplasia
MCs were present in the adventitia of vein grafts from control WT mice (Figs. 1Aand
1B). In KitW-sh/W-sh mice, no MCs were found in either healthy arteries (not shown)
or vein grafts (Fig. 1A). Interestingly, in WT mice perivascular MC count was low 1–3
days following surgery and gradually increased up to 4 weeks, in parallel with neointimal
thickening (Fig. 1C).
At 28 days following surgery, MC deficient KitW-sh/W-sh mouse vein grafts had
developed significantly less neointima when compared to control WTmice (1.07× 105±
0.11× 105 vs. 1.65× 105 ± 0.16× 105 µm2, respectively, P < 0.05; Fig. 2D); confirming
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Figure 1 Perivascular accumulation of MCs in vein graft correlates with neointima formation. MC
anatomical distribution in vein grafts was assessed using (A) Texas Red-Avidin staining (arrows indicate
mast cells; Bar = 100 µm) or (B) Toluidine Blue staining, showing perivascular MC accumulation in
WT vein grafts 28 days following surgery. (C) MC number increased in vein grafts and correlated with
neointima formation up to 4 weeks (n = 4–9). Y axis on the left represents mast cell density, ∗P < 0.05
vs. day 1–3; +P < 0.05 vs. day 7. Y axis on the right represents neointima area: $P < 0.05 vs. day 1–3.
Error bars show the standard error of the mean. Data are analyzed by one-way ANOVA with Tukey’s post
hoc test.
previous findings by De Vries et al. (2013). Importantly, KitW-sh/W-sh mice carrying an
inversion mutation in the c-Kit promoter region (Grimbaldeston et al., 2005) present
other Kit-related abnormalities (Kennedy et al., 2013); therefore, reconstitution of these
mutant mice with bone marrow-derived mast cells is required to selectively restore MC
populations, and to confirm theMC-specificity of the observed neointimal reduction (Sun
et al., 2007a; Sun et al., 2007b; Kennedy et al., 2013). Thus, prior to vein graft implantation,
some KitW-sh/W-sh mice received MC reconstitution via systemic or local injection. The
phenotype of the BMMCs was confirmed by flow cytometry with anti-c-Kit and anti-Fcε
RI antibodies. Over 90% of the cells were double positive for bothmarkers by 4 weeks (Fig.
2A). Consistent with previous reports (Grimbaldeston et al., 2005), systemic injection
achieved multi-organ MC reconstitution (skin shown in Fig. 2B). However, no MCs
were detected in vein grafts or in the aorta 28 days after surgery (Fig. 2B). Conversely,
local injection successfully introduced a MC population around the vein graft at 28
days (Fig. 2C), but not elsewhere (not shown). Intriguingly, local MC reconstitution,
but not systemic reconstitution, restored the amount of neointima formation to that
observed in WT mice grafts (1.41× 105 ± 0.27× 105 vs. 1.65× 105 ± 0.16× 105 µm2,
respectively; Fig. 2D). These data suggest a critical role for the perivascular MCs in
neointimal formation and vein graft disease.
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Figure 2 Reconstitution of WTmast cells to KitW−sh/W−sh mice. (A) WT BMMCs were cultured and
characterized by flow cytometry with anti-FcεRI and anti-c-Kit antibodies. 90% of the living cells were
positive for both FcεRI and c-Kit. (B) Systemic administration of BMMCs via tail vein achieved multiple
organ reconstitution (skin shown in figure), however, no MCs were detected in the vascular wall of
the aorta or in the vein graft 28 days after surgery (Solid bar in left panels = 100 µm; dashed bar in
right panels = 200 µm). (C) Local reconstitution restored mast cells in KitW-sh/W-sh vein grafts (Bar
= 100 µm). No mast cells were found in any other organ or tissue. Data corresponds to twelve mice
per group (WT) and six mice per group (KitW-sh/W-sh +lcMC). Error bars show the standard error of
the mean. No statistical difference was detected between groups by Student’s t-test. (D) MCs increase
neointimal formation in vein grafts. Upper panel: the neointimal area of 28-day-old vein grafts from
wild type (WT) mice, KitW-sh/W-sh mice with or without systemic (KitW-sh/W-sh +sysMC) or local
(KitW-sh/W-sh +lcMC) MC reconstitution. Individual data points represent average value per mouse;
horizontal bars denote mean. ∗P < 0.05 by one-way ANOVA with Tukey’s post hoc test. Lower panel:
representative pictures (H&E) of cross sections of vein graft middle portion from respective groups. The
dashed circle indicates the border of neointima. (Bar= 500 µm).
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Perivascular MCs up-regulated acute inflammation and promoted
cell proliferation
At 7 days, an elevated expression of pro-inflammatory markers was detectable in WT
mouse vein grafts compared to MC deficient mice grafts (Fig. 3A). In particular, the
significantly higher levels of L-selectin (P < 0.05), MCP-1/CCL-2 (P < 0.05), M-CSF
(P < 0.05) and MIP-3α (P < 0.05) observed in WT grafts may increase adhesion
and recruitment of circulating leukocytes and promote cell proliferation. Importantly,
this pattern was not replicated in serum samples (Fig. 3B), once again supporting the
hypothesis that MCs control the local vascular pro-inflammatory response, but exert no
systemic effect.
There is strong evidence for an important role for CCL-2 and M-CSF in vascular
smooth muscle cell proliferation, neointimal formation and vein graft thickening
(Selzman et al., 2002; Schepers et al., 2006; Shiba et al., 2007; Grassia et al., 2009; Fu et
al., 2012). We therefore assessed cell proliferation in mouse vein grafts at day 7, the
peak of cell proliferation in this model as previously demonstrated (Wu, Wadsworth
& Kennedy, 2011), by anti-PCNA staining. WT vein grafts were found to have a higher
percentage of proliferating cells compared to MC deficient mice (P < 0.05; Figs. 3C–3D).
These data demonstrate the key role played by perivascular MCs in orchestrating the
inflammatory-proliferative response leading to accelerated neointima formation in vein
graft disease. Interestingly, no significant difference was observed in vein graft leukocyte
composition between MC deficient andWTmice at 28 days (Fig. 3E). Data supporting a
key role played by the acute vascular inflammatory/proliferative response only during the
first 14 days following surgery.
DISCUSSION
Our data demonstrate a detrimental role played by local perivascular MCs in vein graft
neointimal formation. MC perivascular number correlated with increased neointimal
formation following vein graft surgery. We confirmed that MC deficiency reduced
vein graft neointimal formation, as recently demonstrated by De Vries et al. (2013).
Additionally, we demonstrated that correction of MC deficiency in KitW-sh/W-sh mice by
local but not systemic MC reconstitution restored the reduced neointimal formation. Our
results highlight the importance of the local effects of perivascularMCs in the development
of vein graft disease and form the basis for further investigation on vein graft MC ex vivo
manipulation as a potential therapeutic strategy to improve long-term vein graft patency.
It was not surprising that tail vein injection failed to reconstitute perivascular MCs
in healthy KitW-sh/W-sh mice. Sun et al. (2007a) and Sun et al. (2007b) found that
systemic reconstitution of perivascular MCs could be achieved only in pro-atherosclerotic
KitW-sh/W-sh/low density lipoprotein receptor deficient (Ldlr−/−) mice fed high fat
diet, but not in the same mouse strain fed normal chow diet. Later studies showed that
perivascular MC recruitment was a CCR2-dependent inflammatory process (Zhang et al.,
2012). In contrast, local MC reconstitution was successful in eliminating the difference in
neointimal area betweenWT and KitW-sh/W-shmice.
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Figure 3 MCs increase vascular inflammatory and proliferative response. Cytokine expression profile
in vein graft protein extracts (A) and serum (B) at day 7. ND, Not detectable. Error bars show the
standard error of the mean. ∗P < 0.05 by unpaired Student’s t-test (n = 5 for vein graft samples and
n = 9–10 for serum samples). (C) Proliferating cells in vein grafts at day 7 were identified by anti-PCNA
staining. Sections incubated with the secondary antibody alone were used as negative control (NC). (Bar
= 100 µm). (D) The percentage of proliferating cells was quantified and data presented as mean± SEM.
∗P < 0.05 by unpaired Student’s t-test. (E) The total leukocytes (CD45) as well as the subsets of B cells
(B220), T cells (CD3), CD11b+ve, and CD11c+ve cells in the WT and KitW-sh/W-sh vein grafts were
quantified by flow cytometry at 28 days. Data correspond to five mice per group. Error bars show the
standard error of the mean. No statistical difference was detected between groups by Student’s t-test.
We have previously demonstrated that neointimal formation in the mouse WT
vein graft model is preceded by acute vascular inflammation and cell infiltration and
proliferation during the first 14 days following surgery (Wu, Wadsworth & Kennedy, 2011).
Intriguingly, our current mechanistic analysis demonstrates that adventitial/perivascular
MCs play a pivotal role in orchestrating this early local acute inflammatory and
proliferative response. In particular, MCs promoted vascular inflammation by increasing
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the expression of chemotactic factors (CCL-2, MIP-3α), cytokines (M-CSF) and cell
adhesionmolecules (L-selectin) in the vein graft, all of which, in turn, promote neointimal
formation. Intriguingly, MC deficiency also reduced the levels of bFGF in the vein graft.
Controlled release of bFGF has been reported to improve vein graft long-term patency
(Haraguchi et al., 2007); however, the high circulating levels of bFGF observed in bothMC
WT and deficient mice could contribute to the neutralization of any potential detrimental
effect due to the bFGF reduction inMC deficient grafts.
In order to further define the role that mast cells are playing additional experiments
would be required to assess if the correction ofMC deficiency in KitW-sh/W-sh mice by local
MC reconstitution would be able to restore a proliferative/inflammatory response in the
vein graft to the same level observed in WT mice. In addition, it would be important to
assess which proliferating cells are affected by theMC deficiency.
CONCLUSIONS
In conclusion, our data provide new insight into the role of perivascular MCs in the
regulation of vein graft neointima formation. Coronary artery bypass grafting (CABG)
remains the treatment of choice for high-risk coronary heart disease patients (Serruys et al.,
2009); however, CABG patency is an issue in the long-term (Goldman et al., 2004) and there
is a clear need for novel therapeutic strategies to address CABG graft failure (Bradshaw
& Baker, 2013). We acknowledge that our animal studies require judicious interpretation
when extrapolating to human disease, but our results may form the basis for testing new
specific intra-operative graft ex vivo treatments based onMC targeting in the prevention of
vein graft failure.
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